Monoamine oxidase, phenylethylamine, norepinephrine and schizophrenia

Rj, Wyatt; Karoum, Farouk; Dm, Stoff; Je, Kleinman; Jc, Gillin; Dv, Jeste; Sg, Potkin

doi:10.1111/j.1399-0004.1981.tb00741.x

Cited by 9 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some of these were found to be artifacts of environmental and iatrogenic variables including general effects of longterm medication, and some were never replicated. [12][13][14][15] When brain imaging was introduced into psychiatry, various indices, such as ventricular enlargement, were used to predict outcome, 16,17 but none of these ever made it to clinical utility. Nor has any brain imaging measurement been found to be predictive of a specific disorder.…”

Section: Lessons From the Past: Hypotheses Gone Wrongmentioning

confidence: 99%

Pursuit of the “truth” about mental illness: the significance of findings in neuropsychiatric research, and lessons from the past

DeLisi

2014

Dialogues in Clinical Neuroscience

View full text Add to dashboard Cite

Technology in genetics and brain imaging has advanced so rapidly that it is difficult to be knowledgeable about all the new tools being used in the pursuit of progress toward understanding and treating mental illness. While findings from new studies remain promising, caution is needed with regard to their current applicability to clinical use, both to predict who is likely to become ill and who is likely to respond to medication. A perspective on the past, using schizophrenia as an example, illustrates important findings that were published, had much visibility, and caused a flurry of new related studies, but then slowly disappeared, either to be abandoned as an artifact of the assay or study design, an epiphenomenon, or as simply nonreplicated findings not leading to further progress. Remembering that good science is "the pursuit of the truth" and not joining the latest "bandwagon fad" of "believers" is an important principle to adhere to when participating in the politics of science.

show abstract

Section: Lessons From the Past: Hypotheses Gone Wrongmentioning

confidence: 99%

Pursuit of the “truth” about mental illness: the significance of findings in neuropsychiatric research, and lessons from the past

DeLisi

2014

Dialogues in Clinical Neuroscience

View full text Add to dashboard Cite

show abstract

The association between risk factors for tardive dyskinesia and phenylalanine‐induced abnormal movements in schizophrenia

Schultz

Ellingrod

Fleming

et al. 2001

Human Psychopharmacology

View full text Add to dashboard Cite

We examined whether an oral challenge dose of the amino acid phenylalanine (a dopamine precursor) exacerbates the abnormal movements of tardive dyskinesia (TD). We also examined age, gender, treatment duration, and baseline movement severity in relation to phenylalanine-induced changes in movements. Lastly, we assessed the influence of fasting amino acid levels on phenylalanine-induced movements. In a placebo-controlled fashion, the abnormal involuntary movement scale (AIMS) was obtained on 25 patients before and after a phenylalanine challenge drink. A general linear model determined the relative effects of age, gender, treatment duration, and fasting amino acid levels on the magnitude of induced movements. Age and treatment duration did not affect phenylalanine-induced movements. Lower fasting levels of phenylalanine were associated with greater movements after controlling for age, F = 11.89, p < 0.003. The severity of abnormal movements at baseline also predicted response to phenylalanine, F = 8.62, p = 0.0079. Brain amino acid and neurotransmitter pools are influenced by changes in dietary protein, which may have implications in the development and prevention of movement disorders. This study suggests that fasting amino acid levels may predict differences in vulnerability to movements during an influx of neurotransmitter precursors, perhaps due to long-term compensatory changes in receptor sensitivity. Copyright 2001 John Wiley & Sons, Ltd.

show abstract

β-Phenylethylamine effect on brain and blood catechol-O-methyltransferase activity

Hannan

1986

Pharmacology Biochemistry and Behavior

View full text Add to dashboard Cite

Monoamine oxidase, phenylethylamine, norepinephrine and schizophrenia

Cited by 9 publications

References 35 publications

Pursuit of the “truth” about mental illness: the significance of findings in neuropsychiatric research, and lessons from the past

Pursuit of the “truth” about mental illness: the significance of findings in neuropsychiatric research, and lessons from the past

The association between risk factors for tardive dyskinesia and phenylalanine‐induced abnormal movements in schizophrenia

β-Phenylethylamine effect on brain and blood catechol-O-methyltransferase activity

Contact Info

Product

Resources

About